TNXP Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
13.5M
+96.9%
6.9M
+27.6%
5.4M
+63.8%
3.3M
+64.7%
2.0M
Cost of Revenue
703.0K
-55.4%
1.6M
+49.1%
1.1M
-22.6%
1.4M
-58.2%
3.3M
Gross Profit
12.8M
+142.3%
5.3M
+22.3%
4.3M
+125.3%
1.9M
+250.9%
-1274000
Operating Expenses
55.4M
+18.2%
46.8M
-11.0%
52.6M
+50.4%
35.0M
+29.5%
27.0M
R&D
19.4M
+6.6%
18.2M
+7.5%
16.9M
+82.4%
9.3M
-14.1%
10.8M
SG&A
36.0M
+25.6%
28.6M
-19.8%
35.7M
+38.8%
25.7M
+58.6%
16.2M
Operating Income
-42535000
-2.4%
-41537000
+14.0%
-48286000
-46.0%
-33067000
-16.9%
-28296000
EBITDA
-41916000
-2.3%
-40982000
+14.3%
-47798000
-46.6%
-32606000
-17.2%
-27813000
Net Income
-40552000
-0.9%
-40194000
+14.3%
-46910000
-46.5%
-32010000
-13.2%
-28272000
EPS (Basic)
$-2.44
+16.7%
$-2.93
+25.8%
$-3.95
-10.0%
$-3.59
+7.0%
$-3.86
EPS (Diluted)
$-2.44
+16.7%
$-2.93
+25.8%
$-3.95
-10.0%
$-3.59
+7.0%
$-3.86
Shares (Diluted)
16.6M
+21.4%
13.7M
+15.5%
11.9M
+33.0%
8.9M
+21.8%
7.3M
Tonix Pharmaceuticals (TNXP) โ€” Financials